Hyrimoz

Adalimumab, the active ingredient in Hyrimoz, is a TNF inhibitor presented as an injection solution for subcutaneous use. It is indicated for adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis and hidradenitis suppurativa.

GNH USA supplies Hyrimoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Our global network ensures timely delivery across Europe, Asia and the Americas.

Hyrimoz, a TNF‑α inhibitor, is used to manage several chronic inflammatory diseases. - Rheumatoid arthritis: reduces joint inflammation, pain and structural damage, improving functional ability. - Psoriatic arthritis: alleviates joint swelling and skin lesions, slowing disease progression. - Ankylosing spondylitis: diminishes spinal inflammation and stiffness, enhancing mobility. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve clinical remission and mucosal healing. - Plaque psoriasis: clears skin plaques and reduces scaling. - Hidradenitis suppurativa: decreases lesion formation and associated pain.

Adalimumab may be associated with a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Injection site pain or redness - Upper respiratory tract infection - Headache - Nausea

Serious or Rare Side Effects: - Serious infections such as tuberculosis or sepsis - Malignancies including lymphoma and skin cancers - Autoimmune phenomena like lupus‑like syndrome or demyelinating disorders

Before initiating Hyrimoz, clinicians should consider several precautionary measures to ensure safe use. - Screen for latent tuberculosis: perform TB testing and treat if positive before therapy. - Monitor for infections: advise patients to report signs of serious infection promptly. - Assess vaccination status: administer required vaccines prior to starting treatment; avoid live vaccines during therapy. - Conduct regular laboratory monitoring: check complete blood count and liver function tests periodically. - Store at 2-8 °C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Live vaccines: concurrent use may cause severe infection; avoid administering live vaccines while on therapy. - Antibacterial or antifungal agents that suppress immunity (e.g., azoles): may increase risk of opportunistic infections.

Moderate Interactions (Monitor Closely): - Other immunosuppressants (e.g., methotrexate, azathioprine): may enhance immunosuppression, requiring infection monitoring. - Cytokine‑targeted therapies (e.g., interferon‑beta): may reduce therapeutic response. - Concomitant use of warfarin: monitor INR as inflammation changes can affect anticoagulation.